[Figure 1B](#pntd-0003415-g001){ref-type="fig"} and [Figure 4](#pntd-0003415-g002){ref-type="fig"} are incorrect because they do not show the updated data. The authors have provided the corrected versions here.

![SMSB4 reduces the blood killing of *S. aureus* strain Xen29 in whole blood (A) and pyoderma isolates of *S. aureus* (B).\
SMSB4 promotes bacteria growth in a concentration dependent manner (C) similarly to CVF (D). *S. aureus* Xen29 or pyoderma isolates MRSA strains (HS16, M34), MSSA strains (HS56, M5) were harvested from mid-log growth phase culture. Bacteria (1×10^5^ cfu/ml) were challenged with whole blood pre-treated with either 100 µg/ml SMSB4, positive control 10 µg/ml CVF, negative controls 100 µg/ml BSA or GVB^2+^ buffer only. *S. aureus* cells in PBS only without blood was also included to illustrate that the reduction in bacteria number was due to blood killing (**A**). Numbers of bacteria were counted as cfu/ml at various time points (**A**) or at 3 h (**B**, **C**, **D**). Bacterial recovery was calculated as a percentage of the challenge dose. Results are shown as means ± SEM from three independent experiments. The statistical significance of differences between samples was estimated using two way ANOVA with Tukey's multiple comparison test. \*\*, *p*\<0.01; \*\*\*, *p*\<0.001; \*\*\*\*, *p*\<0.0001, ns, not significant (B).](pntd.0003415.g001){#pntd-0003415-g001}

![Effect of SMSB4 on the depositions of C4b (A), C1q, MBL and properdin (B) on *S. aureus* cells.\
The wells of 96-well microtiter plates were coated with 100 µl aliquots of bacterial cell suspensions containing 5×10^6^ cfu/ml of *S. aureus*. Wells were then incubated with 10% NHS which has been pre-treated with increasing concentrations of either SMSB4 or BSA. Antibodies were detected by ELISA using primary human specific antibodies, followed by HRP-conjugated secondary antibodies, and fluorescence was detected at 490 nm. Results are shown as means ± SEM from three independent experiments. The statistical significance of differences between BSA and SMSB4 treated samples were estimated using two way ANOVA with Sidak's multiple comparison test. \*\*, *p*\<0.01; \*\*\*, *p*\<0.001; ns, not significant (B).](pntd.0003415.g002){#pntd-0003415-g002}
